A Chihuahua or a Muffin? FDA Publicizes Plans for Aggressive Use of Synthetic Intelligence
On Could 8, 2025, FDA introduced the profitable completion of a generative synthetic intelligence (AI) scientific overview pilot program aimed...
Biotechnology & Pharma
MSD and Daiichi Sankyo pull HER3-DXd’s FDA submitting
A 12 months in the past, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the...
TQ Therapeutics acquires Juno GmbH to assist decentralised cell remedy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno...
Memorial Day Weekend 2025 | Cafepharma
We want all our US guests a protected and pleasing vacation weekend. We bear in mind those that have given...
A number of ALS Sufferers See Exceptional Response to ASO Therapy
Sometimes, the objective of ALS remedies is to gradual the illness or halt development. However new information from the antisense...
FOXA2 Drives Metastasis in Small Cell Lung Most cancers
Within the relentless battle in opposition to small cell lung most cancers (SCLC), a quickly advancing and extremely deadly type...
Sanofi to Purchase Vigil Neuroscience to Develop Neurodegenerative Illness Pipeline
Sanofi brand at one in every of skyscraper. Sanofi is a French biopharma firm | Picture Credit score: © Robert...
“Radical Transparency” and “Deregulation” from Trump and RFK Jr.’s FDA . . . Until it’s Helpful to the Machine Business
Final week, FDA revealed a Request for Data (RFI) (right here) searching for enter from the general public on its...
ASCO 25: Roche locations Itovebi marker in breast most cancers
Roche's Itovebi was the primary PI3K inhibitor to get accepted as a first-line remedy for breast most cancers final 12...
MHRA Board meets in Scotland for first time, reinforcing UK-wide well being priorities
The Board of the Medicines and Healthcare merchandise Regulatory Company (MHRA) has met in Scotland for the primary time, marking...
